Erythropoietin: Pleiotropic actions;Aspetti pleiotropici dell'eritropoietina

Recenti Progressi in Medicina

Volumn 101, Issue 6, 2010, Pages 253-267

  Buemi, Michele ^a   Donato, Valentina ^a   Bolignano, Davide ^a  

^a Dipartimento di Medicina Interna   (Italy)

Author keywords

Angiogenesis; Erythropoietin: Pleiotropic actions; Nacrophages; Polimorph nuclear cells; Regenerative medicine

Indexed keywords

ACETYLSALICYLIC ACID; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ANGIOGENESIS; BLOOD CELL; BONE MARROW CELL; BRAIN ISCHEMIA; CARCINOGENESIS; CELL ACTIVATION; CELL PROLIFERATION; CLINICAL TRIAL; ENDOTHELIUM CELL; ERYTHROID CELL; ERYTHROPOIESIS; HEART INFARCTION; HEART MUSCLE CELL; HEART PROTECTION; HEMATOPOIETIC CELL; HORMONE ACTION; HUMAN; INFLAMMATION; LYMPHOCYTE; MACROPHAGE; MEGAKARYOCYTE; MESANGIUM CELL; PHAGOCYTE; PLEIOTROPY; POLYMORPHONUCLEAR CELL; REGENERATIVE MEDICINE; REVIEW; SMOOTH MUSCLE FIBER;

ANEMIA; ANIMALS; ANOXIA; BRAIN; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; ERYTHROID CELLS; ERYTHROPOIESIS; ERYTHROPOIETIN; GENE EXPRESSION REGULATION; HUMANS; ISCHEMIA; KIDNEY; MICE; MODELS, BIOLOGICAL; MYELOID CELLS; MYOCARDIUM; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; ORGAN SPECIFICITY; OXYGEN; RECEPTORS, ERYTHROPOIETIN;

EID: 77954711238     PISSN: 00341193     EISSN: 00341193     Source Type: Journal    
DOI: 10.1701/494.5872     Document Type: Review

References (48)

1. Bunn HF, Poyton RO. Oxygen sensing and molecular adaptation to hypoxia. Physiol Rev 1996; 76: 839-85.
2. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor. J Biol Chem 1995; 270: 1230-7.
3. Wiesener MS, Jürgensen JS, Rosenberger C, et al. Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell populations of different organs. FASEB J 2003; 17: 271-3. Epub 2002 Dec 17.
4. Semenza GL. Involvement of oxygen-sensing pathways in physiological and pathological erythropoiesis. Blood 2009 Jun 3.
5. Goldberg MA, Dunning SP, Bunn HF. Regulation of the erythropoietin gene: evidence that the oxygen sensor is a heme protein. Science 1988; 242: 1412-5.
6. Jaakkola P, Mole DR, Tian YM, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001; 292: 468-72. Epub 2001 Apr 5.
7. Buemi M, Nostro L, Romeo A, et al. From the oxygen to the organ protection: erythropoietin as protagonist in internal medicine. Cardiovasc Hematol Agents Med Chem 2006; 4: 299-311. (Pubitemid 44574841)
8. Chu CY, Cheng CH, Yang CH, Huang CJ. Erythropoietins from teleosts. Cell Mol Life Sci 2008; 65: 3545-52.
9. Paus R, Bodó E, Kromminga A, Jelkmann W. Erythropoietin and the skin: a role for epidermal oxygen sensing? Bioessays 2009; 3: 344-8.
10. Leist M, Ghezzi P, Grasso G, et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004; 305: 239-42.
11. Brines M, Grasso G, Fiordaliso F, et al. Erythropoietin mediates tissue protection through an erythropoietin and commonbeta-subunit heteroreceptor. Proc Natl Acad Sci USA 2004; 101: 14907-12.
12. Brines M, Cerami A. Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. J Intern Med 2008; 264: 405-32.
13. Buemi M, Caccamo C, Nostro L, Cavallaro E, Floccari F, Grasso G. Brain and cancer: the protective role of erythropoietin. Med Res Rev 2005; 25: 245-59. (Pubitemid 40305278)
14. Morishita E, Masuda S, Nagao M, Yasuda Y, Sasaki R. Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience 1997; 76: 105-16.
15. Marti HH, Gassmann M, Wenger RH, et al. Detection of erythropoietin in human liquor: intrinsic erythropoietin production in the brain. Kidney Int 1997; 51: 416-8. (Pubitemid 27088152)
16. Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 2000; 97: 10526-31.
17. Banks WA. Delivery of peptides to the brain: emphasis on therapeutic development. Biopolymers 2008; 90: 589-94.
18. Sadamoto Y, Igase K, Sakanaka M, et al. Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery. Biochem Biophys Res Commun 1998; 253: 26-32.
19. Bernaudin M, Marti HH, Roussel S, et al. A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab 1999; 19: 643-51. (Pubitemid 30161216)
20. Alafaci C, Salpietro F, Grasso G, et al. Effect of recombinant human erythropoietin on cerebral ischemia following experimental subarachnoid hemorrhage. Eur J Pharmacol 2000; 406: 219-25.
21. Koshimura K, Murakami Y, Sohmiya M, Tanaka J, Kato Y. Effects of erythropoietin on neuronal activity. J Neurochem 1999; 72: 2565-72.
22. Konishi Y, Chui DH, Hirose H, Kunishita T, Tabira T. Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic neurons in vitro and in vivo. Brain Res 1993; 609: 29-35. (Pubitemid 23136796)
23. Campana WM, Misasi R, O'Brien JS. Identification of a neurotrophic sequence in erythropoietin. Int J Mol Med 1998; 1: 235-41.
24. Sakanaka M, Wen TC, Matsuda S, et al. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA 1998; 95: 4635-40.
25. Calapai G, Marciano MC, Corica F, et al. Erythropoietin protects against brain ischemic injury by inhibition of nitric oxide formation. Eur J Pharmacol 2000; 401: 349-56. (Pubitemid 30608719)
26. Yamaji R, Okada T, Moriya M, et al. Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA. Eur J Biochem 1996; 239: 494-500. (Pubitemid 26246558)
27. Sirén AL, Fasshauer T, Bartels C, Ehrenreich H. Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system. Neurotherapeutics 2009; 6: 108-27.
28. Maiese K, Hou J, Chong ZZ, Shang YC. Erythropoietin, forkhead proteins, and oxidative injury: biomarkers and biology. Scientific World Journal 2009; 9: 1072-104.
29. Grasso G, Sfacteria A, Meli F, et al. The role of erythropoietin in neuroprotection: therapeutic perspectives. Drug News Perspect 2007; 20: 315-20. (Pubitemid 47345223)
30. Erbayraktar S, Grasso G, Sfacteria A, et al. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc Natl Acad Sci USA 2003; 100: 6741-6. Epub 2003 May 13. Erratum in: Proc Natl Acad Sci USA 2003; 100: 9102.
31. Ehrenreich H, Bartels C, Sargin D, Stawicki S, Krampe H. Recombinant human erythropoietin in the treatment of human brain disease: focus on cognition. J Ren Nutr 2008; 18: 146-53.
32. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 2004; 109: 1004-9. (Pubitemid 38282853)
33. Braunwald E. Shattuck lecture- cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med 1997; 337: 1360-939.
34. Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351: 1285-95.
35. Cohen N, Gorelik O, Almoznino-Sarafian D, et al. Renal dysfunction in congestive heart failure, pathophysiological and prognostic significance. Clin Nephrol 2004; 61: 177-84. (Pubitemid 38396908)
36. Terrovitis JV, Anastasiou-Nana M, Kaldara E, Drakos SG, Nanas SN, Nanas JN. Anemia in heart failure: pathophysiologic insights and treatment options. Future Cardiol 2009; 5: 71-81.
37. Dorn GW 2nd. Novel pharmacotherapies to abrogate postinfarction ventricular remodeling. Nat Rev Cardiol 2009; 6: 283-91.
38. Kazory A, Ross EA. Anemia: the point of convergence or divergence for kidneydisease and heart failure? J Am Coll Cardiol 2009; 53: 639-47.
39. Silverberg DS, Wexler D, Iaina A, Schwartz D. The role of correction ofanaemia in patients with congestive heart failure: a short review. Eur J Heart Fail 2008; 10: 819-23.
40. Noguchi CT, Wang L, Rogers HM, Teng R, Jia Y. Survival and proliferative roles of erythropoietin beyond the erythroid lineage. Expert Rev Mol Med 2008; 10: e36.
41. Buemi M, Allegra A, Aloisi C. Hemodynamic effects of recombinant human erythropoietin. Nephron 1999; 81: 1-4. (Pubitemid 29041709)
42. Buemi M, Allegra A, Squadrito F. Effects of intravenous administration of rHuEPO in rats with haemorrhagic shock. Nephron 1993; 65: 440-3.
43. Allegra A, Giacobbe MS, Corvaia E, et al. Possible role of erythropoietin in the pathogenesis of chronic cor pulmonale. Nephrol Dial Transplant 2005; 20: 2866-7. (Pubitemid 41672301)
44. Weissmann N, Akkayagil E, Quanz K, et al. Basic features of hypoxic pulmonary vasoconstriction in mice. Respir Physiol Neurobiol 2004; 139: 191-202. (Pubitemid 38281122)
45. Efthimiadou A, Pagonopoulou O, Lambropoulou M, Papadopoulos N, Nikolettos NK. Erythropoietin enhances angiogenesis in an experimental cyclosporine A-induced nephrotoxicity model in the rat. Clin Exp Pharmacol Physiol 2007; 34: 866-9.
46. Bayliss PE, Bellavance KL, Whitehead GG, et al. Chemical modulation of receptor signaling inhibits regenerative angiogenesis in adult zebrafish. Nat Chem Biol 2006; 2: 265-73. Epub 2006 Mar 26.
47. Buemi A, Lacquaniti A, Maricchiolo G, et al. Regenerative medicine: does erythropoietin have a role? Current Pharmaceutical Design 2009; 15.
48. Ribatti D, Marzullo A, Gentile A, et al. Erythropoietin/ erythropoietin-receptor system is involved in angiogenesis in human hepatocellular carcinoma. Histopathology 2007; 50: 591-6.